Get complete Patent Opposition Report for Ganymed Pharmaceuticals

Comprehensive Analysis, Strategic Insights & Expert Evaluation – Stay Ahead in Your Patent Challenge.

Download Your Report Now

Explore Ganymed Pharmaceuticals's recently opposed patents, revealing key competitive challenges and strategic patent disputes in the industry. Track oppositions filed by competitors to understand technology battlegrounds and assess potential risks.

Patent NumberGrant DateTitleTotal Oppositions
EP3126381Feb 16, 2022Claudin-6-Specific Immunoreceptors And T Cell Epitopes2
EP3254695Sep 9, 2020Combination Therapy Involving Antibodies Against Claudin 18.2 For Treatment Of Cancer2